Patents by Inventor Celia Patricia Shorrock
Celia Patricia Shorrock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180230209Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralize IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: ApplicationFiled: November 27, 2017Publication date: August 16, 2018Inventors: Phillip David MONK, Lutz JERMUTUS, Celia Patricia SHORROCK, Ralph Raymond MINTER
-
Patent number: 9856317Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralize IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: GrantFiled: March 2, 2016Date of Patent: January 2, 2018Assignee: MEDIMMUNE LIMITEDInventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
-
Publication number: 20160280779Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralize IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: ApplicationFiled: March 2, 2016Publication date: September 29, 2016Inventors: Phillip David MONK, Lutz JERMUTUS, Celia Patricia SHORROCK, Ralph Raymond MINTER
-
Patent number: 9315575Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: GrantFiled: November 8, 2010Date of Patent: April 19, 2016Assignee: MEDIMMUNE LIMITEDInventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
-
Publication number: 20130101595Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.Type: ApplicationFiled: September 5, 2012Publication date: April 25, 2013Applicant: Abbott LaboratoriesInventors: Tariq Ghayer, Richard W. Dixon, Michael Roguska, Michael White, Boris Labkovsky, Jochen Salfeld, Alexander Robert Duncan, Simon Mark Brocklehurst, John Mankovich, Celia Patricia Shorrock, Julia Elizabeth Thompson, Simon Nicholas Lennard
-
Publication number: 20120052060Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: ApplicationFiled: November 8, 2010Publication date: March 1, 2012Applicant: MedImmune LimitedInventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
-
Patent number: 7947273Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: GrantFiled: June 25, 2007Date of Patent: May 24, 2011Assignee: MedImmune LimitedInventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
-
Patent number: 7935343Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralize IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: GrantFiled: July 15, 2004Date of Patent: May 3, 2011Assignee: MedImmune LimitedInventors: Phillip David Monk, Lutz Ulrich Jochen Jermutus, Ralph Raymond Minter, Celia Patricia Shorrock
-
Publication number: 20110008357Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.Type: ApplicationFiled: May 24, 2010Publication date: January 13, 2011Applicant: Abbott LaboratoriesInventors: Tariq Ghayer, Richard W. Dixon, Michael Roguska, Michael White, Boris Labkovsky, Jochen Salfeld, Alexander Robert Duncan, Simon Mark Brocklehurst, John Mankovich, Celia Patricia Shorrock, Julia Elizabeth Thompson, Simon Nicholas Lennard
-
Patent number: 7829090Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: GrantFiled: July 15, 2004Date of Patent: November 9, 2010Assignee: MedImmune LimitedInventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
-
Patent number: 7767207Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.Type: GrantFiled: February 9, 2001Date of Patent: August 3, 2010Assignee: Abbott LaboratoriesInventors: Tariq Ghayer, Richard W. Dixon, Michael Roguska, Michael White, Boris Labkovsky, Jochen Salfeld, Alexander Robert Duncan, Simon Mark Brocklehurst, John Mankovich, Celia Patricia Shorrock, Julia Elizabeth Thompson, Simon Nicholas Lennard
-
Publication number: 20100104563Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.Type: ApplicationFiled: February 9, 2001Publication date: April 29, 2010Inventors: Tariq Ghayer, Richard W. Dixon, Michael Roguska, Michael White, Boris Labkovsky, Jochen Salfeld, Alexander Robert Duncan, Simon Mark Brocklehurst, John Mankovich, Celia Patricia Shorrock, Julia Elizabeth Thompson, Simon Nicholas Lennard
-
Publication number: 20090123478Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: ApplicationFiled: June 25, 2007Publication date: May 14, 2009Inventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter